PARP Inhibitor Biomarkers Market Is Driven By Increasing Prevalence Of Cancer
The PARP inhibitor biomarkers market involves the use of biomarkers to detect PARP inhibitors which are a class of targeted therapy approved for the treatment of cancers like ovarian cancer and breast cancer. PARP inhibitors work by blocking an enzyme called poly (ADP-ribose) polymerase or PARP which is involved in DNA repair. When PARP is blocked, DNA damage caused by chemotherapy or radiation therapy cannot be repaired. This makes cancer cells more sensitive to other DNA damaging anti-cancer treatments. The biomarkers help in identifying patients who are most likely to respond to PARP inhibitors, thereby enabling personalized treatment strategies.
The global PARP inhibitor biomarkers market is estimated to be valued at US$ 5.62 Bn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the PARP Inhibitor Biomarkers Market Demand
are BASF SE, Chembond Chemicals Limited, GE Water and Process Technologies, Kurita Water Industries Ltd., Ion Exchange, Kemira Oyj, AkzoNobel N.V., Solenis, Thermax Ltd., Veolia Water Technologies, Accepta Advanced Environmental Technologies, Hubbard-Hall Inc, Beckart Environmental, Ecolab Incorporated.
The biomarkers market is witnessing increased demand driven by the rising incidence and prevalence of cancer globally. PARP inhibitors have proven effectiveness in breast and ovarian cancers and research is ongoing to explore their potential in other tumor types as well.
Growing awareness about personalized medicine and companion diagnostics is driving several pharmaceutical companies to focus on development of PARP inhibitor biomarkers. The market is also witnessing increased investments to develop novel biomarkers with higher sensitivity and specificity to help identify maximum number of patients who are likely to benefit from PARP inhibitors.
Market Drivers
One of the key drivers of the PARP inhibitor biomarkers market is the increasing prevalence of cancer cases globally. As per statistics, cancer burden is expected to grow significantly in the coming years. Early detection of cancers using biomarkers helps improve patient outcomes. PARP inhibitor biomarkers help oncologists select optimal treatment options for cancer patients by determining their suitability for PARP inhibitors. This drives the demand for such biomarkers.
Get more insights on PARP Inhibitor Biomarkers Market
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian